Fred Alger Management, LLC Hille Vax, Inc. Transaction History

Fred Alger Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$11.86 - $15.93 $142,841 - $191,860	12,044 Added 9.7%	136,166 $1.97 Million
Q1 2024 May 15, 2024	SELL	$14.15 - $19.75 $103,648 - $144,668	-7,325 Reduced 5.57%	124,122 $2.06 Million
Q4 2023 Feb 14, 2024	BUY	$10.35 - $17.11 $111,914 - $185,010	10,813 Added 8.96%	131,447 $2.11 Million
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $389,319 - $560,969	33,591 Added 38.59%	120,634 $1.62 Million
Q1 2023 May 15, 2023	SELL	$14.73 - $18.18 $304,424 - $375,726	-20,667 Reduced 19.19%	87,043 $1.44 Million
Q2 2022 Aug 15, 2022	BUY	$8.7 - $20.18 $937,076 - $2.17 Million	107,710 New	107,710 $1.18 Million

36.3M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $65.2M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.